Key Highlights

• Phase 3 Enrollment Completed Early: Global enrollment in the 4FRONT-2 trial for wet AMD completed roughly four months ahead of schedule with over 500 patients.

• $200 Million Strategic Credit Facility: A non-dilutive credit facility with Hercules Capital extends the company's cash runway into H2 2028.

• Short Squeeze Dynamics: Elevated short interest near 24% of float introduced potential short-squeeze dynamics following the dual positive announcements.

4D Molecular Therapeutics (NASDAQ: FDMT) surged after announcing two major catalysts: completion of global enrollment in its 4FRONT-2 Phase 3 trial of 4D-150 for wet AMD — roughly four months ahead of schedule and over-enrolled with more than 500 patients — alongside a $200 million strategic credit facility with Hercules Capital.

The enrollment milestone, which pushes 52-week topline data to H2 2027, reinforced investor confidence in 4D-150's path to potential approval, as completing enrollment well ahead of schedule is generally viewed as a strong operational execution signal in clinical development.

The non-dilutive debt facility adds financial runway on top of the company's existing $458 million cash position, extending operations into H2 2028, providing meaningful balance sheet visibility without diluting existing shareholders.

With elevated short interest near 24% of float, the dual announcements also introduced potential short-squeeze dynamics, pushing shares to a 52-week intraday high of $13.33 on nearly double average volume.

Shares extended the move with an additional 5% gain in the subsequent session, reflecting sustained investor enthusiasm following the combination of clinical execution strength and improved financial flexibility from the new credit facility.

()